- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kazia Therapeutics Ltd ADR (KZIA)
Track today's live Kazia Therapeutics ADR (KZIA) share price, performance and key data on this page with our current NASDAQ:KZIA stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Kazia Therapeutics ADR share price on the NASDAQ exchange. Use the dropdown to switch exchange for the KZIA share price, head to our technical summary section, which provides analysis on Kazia Therapeutics ADR share price buy/sell indicators using real-time data (or discuss the Kazia Therapeutics ADR (KZIA) stock price today with other investors in the Kazia Therapeutics ADR NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:KZIA share price (ISIN: US48669G3039) to enhance your trading decisions with our free investment tools and resources.
What Is the Kazia Therapeutics Ltd ADR Share Price Today?
The Kazia Therapeutics ADR share price today is 12.3300.
What Is the Stock Symbol for Kazia Therapeutics Ltd ADR
The stock symbol (or 'ticker') for Kazia Therapeutics Ltd ADR is "KZIA."
What Stock Exchange Does Kazia Therapeutics Ltd ADR Trade On?
Kazia Therapeutics Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Kazia Therapeutics Ltd ADR a Good Stock to Buy?
Determining whether Kazia Therapeutics ADR (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:KZIA share price (ISIN: US48669G3039) to enhance your trading decisions with our free investment tools and resources.
What Is the Kazia Therapeutics Ltd ADR Share Price Today?
The Kazia Therapeutics ADR share price today is 12.3300.
What Is the Stock Symbol for Kazia Therapeutics Ltd ADR
The stock symbol (or 'ticker') for Kazia Therapeutics Ltd ADR is "KZIA."
What Stock Exchange Does Kazia Therapeutics Ltd ADR Trade On?
Kazia Therapeutics Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Kazia Therapeutics Ltd ADR a Good Stock to Buy?
Determining whether Kazia Therapeutics ADR (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.9000
12.7900
52 wk Range
4.8600
17.4000
KZIA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.900012.7900
52 wk Range
4.860017.4000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KZIA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
27.8688
Upside
+126.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Form 6K Kazia Therapeutics Ltd ADR For: 2 June- Investing.com
Kazia Therapeutics names James Levine as CFO- Investing.com
Novogen Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 27.8688
(+126.02% Upside)
Earnings
Latest Release
07/11/2025
EPS / Forecast
-7.64 / -221.00
Revenue / Forecast
1.81M / --
Compare KZIA to Peers and Sector
Metrics to compare | KZIA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKZIAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.8x | 10.1x | −0.4x | |
PEG Ratio | −0.11 | 0.05 | 0.00 | |
Price/Book | 4.3x | 1.1x | 2.6x | |
Price / LTM Sales | 105.5x | 1.6x | 3.0x | |
Upside (Analyst Target) | 151.7% | 246.9% | 51.8% | |
Fair Value Upside | Unlock | 2.8% | 7.2% | Unlock |
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Kazia Therapeutics ADR (NASDAQ: KZIA) Share Price Today?
The Kazia Therapeutics ADR stock price today is 12.3300 USD.
What Stock Exchange Does Kazia Therapeutics ADR (KZIA) Trade On?
Kazia Therapeutics ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Kazia Therapeutics ADR?
The stock symbol (also called a 'ticker') for Kazia Therapeutics ADR is "KZIA."
What Is the Current Kazia Therapeutics ADR Market Capitalisation?
As of today, Kazia Therapeutics ADR (NASDAQ: KZIA) market cap is 137.1200M USD.
What Is Kazia Therapeutics ADR's (KZIA) Earnings Per Share (TTM)?
The Kazia Therapeutics ADR EPS is currently -10.2231 (Trailing Twelve Months).
Is KZIA a Buy or Sell From a Technical Analyst Perspective?
Based on today's Kazia Therapeutics ADR moving averages and other technical indicators, the daily buy/sell signal for KZIA stock is Neutral.
How Many Times Has Kazia Therapeutics ADR Stock Split?
Kazia Therapeutics ADR has split 4 times. (See the KZIA stock split history page for full effective split date and price information.)
How Many Employees Does Kazia Therapeutics ADR Have?
Kazia Therapeutics ADR has 6 employees, based on their latest Companies House report.
What is the current trading status of Kazia Therapeutics ADR (NASDAQ: KZIA)?
As of 06/08/2026, Kazia Therapeutics ADR (KZIA) is trading at a share price of 12.3300 USD, with a previous close of 12.0000 USD. The stock has fluctuated within a day range of 11.9000 USD to 12.7900 USD, while its 52-week range spans from 4.8600 USD to 17.4000 USD.
What Is Kazia Therapeutics ADR (KZIA) Price Target According to Analysts?
The average 12-month price target for Kazia Therapeutics ADR is 27.8688 USD, with a high estimate of 34.18561931 USD and a low estimate of 17.65171606 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +126.02% Upside potential.
What Is the KZIA Premarket Price?
KZIA's last pre-market stock price is 12.1000 USD. The pre-market share volume is 600.0000, and the stock has decreased by 0.1000, or 0.8300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.